Article - Drug-Eluting Stent Solutions
Albert E. Raizner, MD, FACC, FSCAI
07/01/2004
Republished courtesy of Cath Lab Digest.
Q - How will DES impact the practice of interventional cardiology?
A - With the advent of drug-eluting stents (DES), we expect the population of patients with restenosis to decline significantly. So, physicians have...(download the PDF to read more)
Download PDF
Article - Evaluating DES Registries and Randomized Clinical Trials
Ron Waksman, MD
06/01/2006
Reprinted with permission from Cath Lab Digest
Q - How do registries differ from randomized controlled trials (RCTs)?
A - Unlike RCT’s, registries are not built on randomization and therefore may….( download the pdf for more information)
Download PDF
Article - Examining the Anti-Proliferative Drug Paclitaxel
Alan W. Heldman, MD
09/01/2004
Republished courtesy of Cath Lab Digest.
Q - Dr. Heldman, paclitaxel is a drug that is eluted from some coronary stent systems. Could you give us a brief history of this drug?
A - The drug paclitaxel was discovered in the course of a systematic screening of...(download the pdf to read more)
Download PDF
Article - High-Risk Coronary Lesions Simulation Training
Mark A. Turco, MD, FACC
01/01/2005
Reprinted with permission from Cath Lab Digest.
New simulation training courseware that enables participants to perform two high-risk cases. Case one is a tortuous anatomy Type C lesion in the right coronary artery (RCA). Case two is a complex multi-vessel case.
Download PDF
Article - Late Loss
John M. Lasala, MD, PhD, FACC, FACP
11/01/2004
Republished courtesy of Cath Lab Digest
Q - Some current clinical trials use late loss as a key data point. Can you help us understand what late loss is?
A - Late loss is the difference in millimeters between the diameter of a stented segment...(download the PDF to read more)
Download PDF
Article - Medical Simulation: A Key Training for Fellows and Experienced Interventionalists
James B. Hermiller, MD, FACC, FSCAI
11/01/2004
Repbublished courtesy of Diagnostic and Invasive Cardiology
With the continued introduction of new, novel techniques for the treatment of cardiovascular disease, training has taken on a more important role.
Download PDF
Article - Paclitaxel as a Locally Delivered Therapy to Prevent Restenosis
Dr. A Heldman
03/29/2004
Republished courtesy of TCTMD and Dr. Heldman
The TAXUS IV trial results served as the pivotal clinical data set for the recent FDA approval of the TAXUS Express² Paclitaxel-Eluting Coronary Stent System. Before this remarkable study, however, many years of preclinical and clinical...(read more)
Download PDF
Article - Reviewing the TAXUS VI Clinical Trial Results
Keith D. Dawkins, MD, FRCP, FACC
10/01/2004
Republished courtesy of Cath Lab Digest
Q - How does the TAXUS VI clinical trial fit into the TAXUS® Stent clinical trial series?
A - The TAXUS VI clinical trial is the most recent of six clinical trials over four years to study the safety and efficacy...(download the PDF to read more)
Download PDF
Article - TAXUS Clinical Trials: TCT Recap
Gregg W. Stone, MD
12/01/2004
Reprinted with permission from Cath Lab Digest.
Q - Dr. Stone, at the recent TCT Conference, findings were presented on a variety of TAXUS Clinical Trials. What trials did you report on, and what were some of the overall findings?
A - At TCT my colleagues and I...(download the PDF to read more)
Download PDF
Product Specifications
View Spec Sheet
TAXUS Clinical Trials Summary
The TAXUS Express² clinical summary brochure highlights Boston Scientific's rigorous drug-eluting stent program of multi-center trials designed to demonstrate the safety and efficacy of the TAXUS Express² Paclitaxel-Eluting Coronary Stent System.
Download PDF
